Global consortium will advance precision medicine research through
metabolic phenotyping
MILFORD, Mass.--(BUSINESS WIRE)--Nov. 30, 2016--
A consortium of leading research centers from six different countries
today launched the International
Phenome Centre Network (IPCN) at the 2016 World Innovation Summit
for Health (WISH) in Doha, Qatar. Through its commitment to harmonized
metabolic phenotyping methods, the IPCN will tackle some of the most
pressing global health challenges, such as autism, cancer, diabetes,
dementia and obesity. Supporting the network with its chromatography and
mass spectrometry technologies and expertise, Waters Corporation
(NYSE:WAT) is a founding corporate partner of the IPCN.
An advance in precision medicine research, metabolic phenotyping
examines the dynamic interactions between our genes, environments,
microbiomes, diets and lifestyles and their impact on disease. The
research is made possible through advanced analytical science, including
mass spectrometry.
Waters is a world leader in mass spectrometry technologies and methods.
It collaborates with IPCN institutions around the world to apply
cutting-edge analytical and mathematical approaches to study robust and
harmonized data representing the world’s diverse populations. The
results could unravel the molecular underpinnings of disease and inform
the development of new therapies and global public health policies.
“We are excited by the revolutionary potential of the International
Phenome Centre Network to harmonize the way researchers around the world
collect and assess data through metabolic phenotyping,” said Rohit
Khanna, Senior Vice President, Applied Technology, at Waters
Corporation. “It has been a privilege working with world-class
institutions to develop and use technologies that will drive solutions
to our most complex global health care challenges.”
Initiated by the MRC-NIHR National Phenome Centre (NPC) at Imperial
College London, the IPCN includes more than a dozen international
partners with regional, multi-institutional hubs in Australia, Canada,
China, Japan, Singapore, Taiwan, the United States and the United
Kingdom.
Waters has long supported collaboration and the harmonization of
research techniques and standards across geographies and through
partnerships with industry, governments, academic centers and health
systems. It has provided funding support for metabolic profiling
training centers, including the Imperial International Phenome Training
Centre.
“We are grateful for Waters’ collaboration in the creation
of internationally harmonized centers of analytical science, focused on
understanding gene-environment interactions that underpin disease risk,
the comparative biology of major diseases and addressing unmet
healthcare and medical needs,” said Jeremy Nicholson, Director of the
NPC and Head of Department of Surgery and Cancer at Imperial CollegeLondon. “Waters’ expertise and international leadership in mass
spectrometry and analytical science has been instrumental to the
network’s success.”
About Waters Corporation (www.waters.com)
Waters
Corporation (NYSE:WAT) develops and manufactures advanced analytical and
material science technologies for laboratory dependent organizations.
For more than 50 years, the company has pioneered a connected portfolio
of separations science, laboratory information management, mass
spectrometry and thermal analysis systems.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161130005935/en/
Source: Waters Corporation
For Waters Corporation
Jeff Tarmy, 508-482-2268
Corporate
Communications
jeff_tarmy@waters.com